Compare Citius Pharmaceuticals Inc (CTXR) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares Self-Driving EV and Tech — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while iShares Self-Driving EV and Tech trades at $36.65. The key difference: iShares Self-Driving EV and Tech is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | IDRV | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $45.48 |
52-Week Low | $0.53 | $32.13 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
IDRV trades at $36.35, down 1.38% with a bearish technical signal from moving averages. The ETF shows neutral oscillators but lacks disclosed fundamental ratios. Recent news highlights strong global EV sales growth, particularly in China and Europe, driven by high fuel prices and policy support, though U.S. adoption lags.
Outlook is mixed: positive EV industry momentum contrasts with technical weakness and U.S. market challenges. Key risks include regulatory shifts, competition, and reliance on macroeconomic factors. Investors should weigh sector growth against ETF-specific performance and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →
